Stocks · News reference
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $306 to $316.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $242 to $251.
Read original at benzingaRBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $304 to $297.
Read original at benzingaAxsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.
Read original at benzinga